Most breast cancer patients have not benefitted from immune checkpoint blockade because of conflicting results between studies and the lack of reliable biomarkers.10 However, a recent clinical trial showed increased progression-free survival in TNBC patients positive for PD-L1 who were treated with a combination of atezolizumab and nab-paclitaxel as first line therapy.11 The gene discussed is CD274; the disease is breast carcinoma.